Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EYPT | US
0.12
0.81%
Healthcare
Biotechnology
30/06/2024
17/04/2026
14.93
15.00
15.25
14.76
EyePoint Pharmaceuticals Inc. a pharmaceutical company engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States China and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery including EYP-1901 an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals Inc. in March 2018. EyePoint Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Watertown Massachusetts.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
32.5%1 month
52.1%3 months
72.2%6 months
70.0%-
-
2.59
0.10
0.07
-11.49
6.64
-
-96.53M
799.03M
799.03M
-
-364.52
-
4.10
-60.81
14.75
19.56
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.68
Range1M
3.43
Range3M
7.05
Rel. volume
1.33
Price X volume
17.32M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| uniQure N.V | QURE | Biotechnology | 17.58 | 856.10M | 4.58% | n/a | 550.36% |
| Maravai LifeSciences Holdings Inc | MRVI | Biotechnology | 3.39 | 855.08M | -0.59% | n/a | 128.60% |
| Theravance Biopharma Inc | TBPH | Biotechnology | 17.23 | 842.93M | 2.68% | n/a | 24.09% |
| Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 6 | 825.53M | -8.12% | n/a | 0.00% |
| Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 15.82 | 825.24M | 4.15% | n/a | 3.62% |
| SPRY | SPRY | Biotechnology | 8.18 | 792.98M | 0.00% | n/a | 0.07% |
| Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 3.52 | 783.08M | 1.44% | n/a | 29.02% |
| MeiraGTx Holdings plc | MGTX | Biotechnology | 10.12 | 781.10M | 6.75% | n/a | 109.40% |
| MannKind Corporation | MNKD | Biotechnology | 2.84 | 780.99M | 3.27% | 132.00 | -149.80% |
| Omeros Corporation | OMER | Biotechnology | 13.44 | 778.81M | 7.18% | n/a | -356.63% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.54 | 805.08M | 5.73% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.34 | 732.76M | 5.14% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.37 | 724.04M | 5.53% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.67 | 563.50M | 1.69% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.54 | 530.55M | 7.32% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.4 | 388.61M | 6.32% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.69 | 347.04M | 5.78% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.35 | 320.92M | 3.40% | n/a | 174.23% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.94 | 275.66M | 4.06% | 13.23 | 0.00% |
| Urban One Inc | UONEK | Broadcasting - Radio | 5.1665 | 273.86M | 6.09% | n/a | 268.43% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.49 | - | Cheaper |
| Ent. to Revenue | 6.64 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.59 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 72.18 | - | Par |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 799.03M | - | Emerging |